Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Heterocyclic compounds
8399451 Heterocyclic compounds
Patent Drawings:

Inventor: Gilmore, et al.
Date Issued: March 19, 2013
Application:
Filed:
Inventors:
Assignee:
Primary Examiner: Chu; Yong
Assistant Examiner:
Attorney Or Agent: Greenblatt; Gary D.
U.S. Class: 514/210.2; 514/236.2; 514/254.03; 514/256; 514/318; 514/326; 514/342; 514/364; 544/138; 544/333; 544/369; 546/194; 546/209; 546/271.1; 548/131; 548/950
Field Of Search: 514/210.2; 514/364; 544/138; 544/333; 546/209; 546/194; 548/131; 548/950
International Class: A61K 31/4245; A61K 31/4439; A61K 31/506; C07D 417/14; C07D 413/14; A61K 31/497; A61K 31/5377; A61K 31/4545; A61K 31/454; C07D 413/04
U.S Patent Documents:
Foreign Patent Documents: WO9605193; WO9806694; WO2004/035538; WO2004/058149; WO2004/071442; WO2004/103279; WO2004/103306; WO2004/103309; WO2004/113330; WO2005/000833; WO2005/032465; WO2005/058848; WO2006/047195; WO2006/088944; WO2006/100631; WO2006/100633; WO2006/115188; WO2006/131336; WO2006/137019; WO2007/024922; WO2007/080542; WO2007/085451; WO2007/091396; WO2007/116866; WO2008/016674; WO2008/023783; WO2008/028937; WO2008/029306; WO2008/029370; WO2008/029371; WO2008/030843; WO2008/035239; WO 2008029370; WO2008/037476; WO2008/064315; WO2008/074820; WO2008/074821; WO2008/076356; WO2008/079382; WO2008/091967; WO2008/114157; WO2009/011850; WO2009/043889; WO2009/043890; WO2009/057079; WO 2009/080663; WO2009/151529; WO2010/041655; WO2010/064707; WO2010/069949; WO2010/072352; WO2010/072712; WO2010/081692; WO2010/085581; WO2010/085582; WO2010/085584; WO2010/113528; WO2010/113796
Other References: Hale et al., Bioorg. Med. Chem. Lett., 14:3501 (2004). cited by applicant.
Sanna et al., J. Biol. Chem., 279:13839 (2004). cited by applicant.
Anliker et al., J. Biol. Chem., 279:20555 (2004). cited by applicant.
Mandala et al., J. Pharmacol. Exp. Ther., 309:758 (2004). cited by applicant.
Brinkman et al., J. Biol. Chem., 277:21453 (2002). cited by applicant.
Mandala et al., Science, 296:346 (2002). cited by applicant.
Fujino et al., J. Pharmacol. Exp. Ther., 305:70 (2003). cited by applicant.
Brinkmann et al., Am. J. Transplant., 4:1019 (2004). cited by applicant.
Webb et al., J. Neuroimmunol., 153:108 (2004). cited by applicant.
Morris et al., Eur. J. Immunol., 35:3570 (2005). cited by applicant.
Chiba, Pharmacology & Therapeutics, 108:308 (2005). cited by applicant.
Kahan et al., Transplantation, 76:1079 (2003). cited by applicant.
Kappos et al., N. Engl. J. Med., 355:1124 (2006). cited by applicant.
Koyrakh et al., Am. J. Transplant., 5:529 (2005). cited by applicant.
Hale et al., J. Med. Chem., 47:6662 (2004). cited by applicant.
Rosen et al., Trends Immunol., 28:102 (2007). cited by applicant.
International Search Report dated Nov. 24, 2010. cited by applicant.









Abstract: Disclosed are compounds of Formula (I) ##STR00001## or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is ##STR00002## Q is a substituted 5-membered monocyclic heteroaryl group; W is CH.sub.2, O, or NH; and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
Claim: What is claimed is:

1. A compound of Formula (I): ##STR00333## or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: m is 1 or 2; n is 1 or 2; wherein: W is CH.sub.2 when(m +n) is 2 or 3; or W is CH.sub.2, O, or NH when (m +n) is 4; R.sub.1 is --(CR.sub.dR.sub.d).sub.aOH, --(CR.sub.dR.sub.d).sub.aCOOH, --(CR.sub.dR.sub.d).sub.aC(O)NR.sub.cR.sub.c, --(CR.sub.dR.sub.d).sub.aC(O)NHS(O).sub.2(C.sub.1-3alkyl),--(CR.sub.dR.sub.d).sub.aC(O)NHS(O).sub.2(aryl), or --(CR.sub.dR.sub.d).sub.atetrazolyl; each R.sub.2 is independently halo, C.sub.1-4alkyl, C.sub.1-2haloalkyl, --OH, C.sub.1-3alkoxy, and/or --NR.sub.cR.sub.c; R.sub.3 and R.sub.4 are independently Hand/or C.sub.1-6alkyl; or R.sub.3 and R.sub.4 together with the carbon atom to which they are attached, form a 3- to 6-membered ring containing zero or 1 heteroatom selected from O and N; R.sub.5 is H or C.sub.1-4alkyl; each R.sub.6 is independentlyC.sub.1-3alkyl, halo, C.sub.1-3haloalkyl, --CN, --OH, C.sub.1-3alkoxy, and/or C.sub.1-3haloalkoxy; A is ##STR00334## Q is a 5-membered monocyclic heteroaryl group having 1 to 3 heteroatoms independently selected from N, O, and S, wherein said heteroarylgroup is substituted with R.sub.a and zero or 1 R.sub.b, provided that Q is not 2-furan-2-yl, 4-thiazolyl, 4-oxazolyl, or 1,2,3-triazolyl; R.sub.ais C.sub.2-6alkyl, C.sub.2-4haloalkyl, C.sub.3-6cycloalkyl, tetrahydropyranyl, or a cyclic group selectedfrom phenyl, benzyl, and 5- to 6-membered monocyclic heteroaryl groups having 1 to 3 heteroatoms independently selected from N, O, and S, wherein said cyclic group is substituted with zero, 1, 2, or 3 substituents independently selected from halo, --CN,--OH, C.sub.1-4alkyl, C.sub.1-4alkoxy, C.sub.1-3haloalkyl, and C.sub.1-2haloalkoxy; R.sub.b is C.sub.1-3alkyl or C.sub.1-3haloalkyl, provided that if R.sub.a is alkyl then R.sub.b is C.sub.1-3haloalkyl; each R.sub.c is independently H and/orC.sub.1-4alkyl; each R.sub.d is independently H, --OH, C.sub.1-4alkyl, C.sub.1-4haloalkyl, and/or C.sub.1-4alkoxy; a is zero, 1, 2, or 3; t is zero, 1, 2, 3, or 4; and x is zero, 1, or 2; with the proviso that the following compounds are excluded:##STR00335##

2. The compound according to claim 1 or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R.sub.3 and R.sub.4 are independently H and/or C.sub.1-4alkyl; R.sub.a is C.sub.2-4alkyl, C.sub.2-3fluoroalkyl, C.sub.4-6cycloalkyl,tetrahydropyranyl, or a cyclic group selected from phenyl, benzyl, and 5- to 6-membered monocyclic heteroaryl groups having 1 to 2 heteroatoms independently selected from N, O, and S, wherein said cyclic group is substituted with zero, 1, 2, or 3substituents independently selected from halo, --CN, C.sub.1-4alkyl, C.sub.1-3alkoxy, --CF.sub.3, and --OCF.sub.3; R.sub.b is C.sub.1-3alkyl or --CF.sub.3, provided that if R.sub.a is C.sub.2-4alkyl then R.sub.b is --CF.sub.3; and each R.sub.d isindependently H, --OH, and/or --CH.sub.3.

3. The compound according to claim 1 or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R.sub.1 is --(CR.sub.dR.sub.d).sub.aOH, --(CR.sub.dR.sub.d).sub.aCOOH, or --C(O)NR.sub.cR.sub.c; each R.sub.2 is independently F,Cl, --OH, and/or C.sub.1-4alkyl; each R.sub.6 is independently C.sub.1-2alkyl, F, Cl, C.sub.1-2haloalkyl, --CN, --OH, C.sub.1-2alkoxy, and/or C.sub.1-2haloalkoxy; R.sub.ais C.sub.2-4alkyl, C.sub.2-3fluoroalkyl, cyclohexyl, tetrahydropyranyl, or acyclic group selected from phenyl, benzyl, and 5- to 6-membered monocyclic heteroaryl groups having 1 to 2 heteroatoms independently selected from N, O, and S, wherein said cyclic group is substituted with zero, 1, 2, or 3 substituents independentlyselected from halo, --CN, C.sub.1-4alkyl, C.sub.1-2alkoxy, --CF.sub.3, and --OCF.sub.3; each R.sub.d is independently H, --OH, C.sub.1-2alkyl, C.sub.1-3fluoroalkyl, and/or C.sub.1-2alkoxy; and t is zero, 1, 2, or 3.

4. The compound according to claim 1 or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Q is a heteroaryl group selected from thiophenyl, pyrazolyl, isoxazolyl, 5-thiazolyl, imidazolyl, and isothiazolyl, wherein saidheteroaryl group is substituted with R.sub.a and zero or 1 R.sub.b.

5. The compound according to claim 1 having formula (Ie): ##STR00336## or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R.sub.1 is --CH.sub.2OH, --CH.sub.2CH.sub.2OH, --(CH.sub.2).sub.aCOOH, --C(CH.sub.3).sub.2COOH, or--C(O)N(ethyl).sub.2; R.sub.2 is F, --OH, or --CH.sub.3; R.sub.3 and R.sub.4 are independently H and/or --CH.sub.3; R.sub.5 is H or --CH.sub.3 R.sub.6 is --CF.sub.3; Q is a heteroaryl group selected from thiophenyl, pyrazolyl, isoxazolyl,5-thiazolyl, imidazolyl, and isothiazolyl, wherein said heteroaryl group is substituted with R.sub.a and zero or 1 R.sub.b; R.sub.ais C.sub.3-4alkyl, --CH.sub.2CF.sub.3, cyclohexyl, tetrahydropyranyl, or a cyclic group selected from phenyl, pyridinyl,and pyrimidinyl, wherein said cyclic group is substituted with zero to 2 substituents independently selected from F, Cl, Br, C.sub.1-3alkyl, --CF.sub.3,and --OCH.sub.3; R.sub.b is C.sub.1-3alkyl or --CF.sub.3, provided that if R.sub.a is C.sub.3-4alkylthen R.sub.b is --CF.sub.3; a is zero, 1, or 2; t is zero or 1; and x is zero or 1.

6. The compound according to claim 5 or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R.sub.1 is --(CH.sub.2).sub.aOH, --(CH.sub.2).sub.aCOOH, --C(CH.sub.3).sub.2COOH, or --C(O)N(ethyl).sub.2; R.sub.2 is F, --OH, or--CH.sub.3; R.sub.3 is H; R.sub.4 is H; R.sub.5 is H or --CH.sub.3; R.sub.6 is --CF.sub.3; and t is zero or 1.

7. The compound according to claim 1 represented by formula (If): ##STR00337## or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R.sub.1 is --(CH.sub.2).sub.aCOOH; and p is 1, 2, or 3.

8. The compound according to claim 7 represented by formula (If): ##STR00338## or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R.sub.1 is --(CH.sub.2).sub.aCOOH; and p is 1, 2, or 3.

9. The compound according to claim 8 represented by formula (Ig): ##STR00339## or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R.sub.1 is --(CH.sub.2).sub.aCOOH; and a is zero, 1, or 2.

10. The compound of claim 1 or a salt thereof, wherein said compound is selected from: 1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)- 1 ,2,4-oxadiazol-3-yl) phenyl)ethyl)azetidine-3-carboxylic acid (1); 1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-y- l)phenyl)ethyl)piperidine-2-carboxylic acid (2); 1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-y- l) phenyl)ethyl)piperidine-3-carboxylic acid (3); (3S)-1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazo- l-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (4); (3R)-1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazo- l-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid(5); 1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-y- l)phenyl)ethyl)pyrrolidine-3-carboxylic acid (6); (2R)-1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazo- l-3-yl)phenyl)ethyl)azetidine-2-carboxylic acid(7); 2-(1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-- 3-yl)phenyl)ethyl)piperidin-2-yl)acetic acid (8 and 9); 2-((2S)-1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadi-azol-3-yl)phenyl)ethyl)pyrrolidin-2-yl)acetic acid (10); 4-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl1)-1,2,4-oxadiazol-3-- yl)phenyl)ethyl) morpholine-2-carboxylic acid (11); 2-((3S)-1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadi- azol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid (12); 2-((3R)-1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadi- azol-3-yl)phenyl)ethyl)piperidin-3-yl)aceticacid (13); (S)-1-(S)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1- ,2,4-oxadiazol-3-yl)phenyl)ethyl) piperidine-3-carboxylic acid (14); (S)-1-(R)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1-,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (15); (3S)-1-(2-hydroxy-2-(4-(5-(3-(pyridin-2-yl)-4-(trifluoromethyl) isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (16); (3S)-1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2- ,4-oxadiazol-3-yl)phenyl)propyl)piperidine-3-carboxylic acid (17); 2-((3R)-1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)--1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid (18 and 19); (3S)-1-(2-hydroxy-2-(4-(5-(5-isobutyl-4-(trifluoromethyl)isoxazol-3-yl)-1- ,2,4-oxadiazol-3-yl)phenyl)ethyl) piperidine-3-carboxylic acid (20); 4-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-y- l)phenyl)ethyl)piperazine-2-carboxylic acid (21); 2-(1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-- 3-yl)phenyl)ethyl) piperidin-3-yl)acetic acid (22); 1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-y- l)phenyl)ethyl)piperidin-3-ol (23); N,N-diethyl-1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-o- xadiazol-3-yl)phenyl)ethyl) piperidine-3-carboxamide (24); 1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl) isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)azetidine-3-carboxylic acid (25); (3S)-1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2-,4-oxadiazol-3-yl)-3-(trifluoromethyl)phenyl)ethyl)piperidine-3-carboxylic acid (26); 2-(1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4- -oxadiazol-3-yl)phenyl)ethyl)azetidin-3-yl)acetic acid (27); 4-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-ox- adiazol-3-yl)phenyl)ethyl)morpholine-2-carboxylic acid (28); 2-(4-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4--oxadiazol-3-yl)phenyl)ethyl)morpholin-3-yl)acetic acid (29); 2-(3-(hydroxymethyl)piperidin-1-yl)-1-(4-(5-(3-phenyl-4-(trifluoromethyl)- isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethanol (30); 2-(3-(2-ydroxyethyl)piperidin-1-yl)-1-(4-(5-(3-phenyl-4-(trifluoromethyl)- isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethanol (31); 5-hydroxy-1-(2-hydroxy -2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl-)phenyl)ethyl)piperidine-3-carboxylic acid (32); 2-(4-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4- -oxadiazol-3-yl)phenyl)ethyl)morpholin-2-yl)acetic acid (33); 3-fluoro-1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)- -1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (34); 2-((3R)-1-(2-hydroxy-2-(4-(5-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid (35); (3S)-1-(2-hydroxy-2-(4-(5-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-1,2- ,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (36); (3S)-1-(2-hydroxy-2-(4-(5-(3-(6-methylpyridin-2-yl)-4-(trifluoromethyl)is- oxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (37); 1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-ox-adiazol-3-yl)phenyl)ethyl)-3-methylpiperidine-3-carboxylic acid (38); 3-hydroxy-1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl- )-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (39); 3-(1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4- -oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)propanoic acid (40); (2R)-1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2-,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-2-carboxylic acid (41); 1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-ox- adiazol-3-yl)phenyl)ethyl)-6-methylpiperidine-2-carboxylic acid (42); (3S)-1-(2-hydroxy-2-(4-(5-(5-(pyridine-2-yl)thiophen-2-yl)-1,2,4-oxadiazo- l-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (43); (3S)-1-(2-hydroxy-2-(4-(5-(1-phenyl-5-propyl -1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxyl- icacid (44); (3S)-1-(2-hydroxy-2-(4-(5-(5-methyl-1-phenyl-1H-pyrazol-3-yl)-1,2,4-oxadi- azol-3-yl)phenyl)ethyl) piperidine-3-carboxylic acid (45); (3S)-1-(2-hydroxy-2-(4-(5-(4-methyl-2-phenylthiazol-5-yl)-1,2,4-oxadiazol--3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (46); (3S)-1-(2-hydroxy-2-(4-(5-(1-phenyl -1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl) phenyl)ethyl)piperidine-3-carboxylic acid (47); (3S)-1-(2-(4-(5-(3-(4-chlorophenyl)-1H-pyrazol-5-yl)-1,2,4-oxadiazol-3-yl-)phenyl)-2-hydroxyethyl)piperidine-3-carboxylic acid (48); (3S)-1-(2-(4-(5-(3-(2-chlorophenyl)-1H-pyrazol-5-yl)-1,2,4-oxadiazol-3-yl- )phenyl)-2-hydroxyethyl)piperidine-3-carboxylic acid (49); (3S)-1-(2-hydroxy-2-(4-(5-(1-methyl-3-phenyl-1H-pyrazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl) ethyl)piperidine-3-carboxylic acid (50); (3S)-1-(2-(4-(5-(5-ethyl-1-(pyridin-2-yl)-1H-pyrazol-4-yl)-1,2,4-oxadiazo- l-3-yl)phenyl)-2-hydroxyethyl)piperidine-3-carboxylic acid (51); (3S)-1-(2-hydroxy-2-(4-(5-(5-methyl-1-phenyl- 1H -pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (52); (3S)-1-(2-(4-(5-(5-(4-chlorophenyl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)ph- enyl)-2-hydroxyethyl)piperidine-3-carboxylicacid (53); 2-((3R)-1-(2-hydroxy-2-(4-(5-(3-(pyridin-2-yl)-4-(trifluoromethyl)isoxazo- l-5-y1)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl) acetic acid (54); (3S)-1-(1-hydroxy-2-methyl -1-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)propan-2-yl)piperidine-3-carbo- xylic acid, TFA (55); 2-((3R)-1-(2-hydroxy-2-(4-(5-(3-(pyridin-2-yl)-4-(trifluoromethyl) isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid (56); (S)-1-((S)-2-hydroxy-2-(4-(5-(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-y- l)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (57); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(1-phenyl-5-(trifluoromethyl)-1H-pyrazol--4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid, HCl (58); 2-((R)-1-((S)-2-(4-(5-(1-cyclohexyl-5-(trifluoromethyl)-1H-pyrazol-- 4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl)acetic acid, HCl(59); 2-((3R)-1-((2S)-2-(4-(5-(1-(3-chloropyridin-2-yl)-5-(trifluoromethyl)-1H-- pyrazol-4-yl)-1,2,4-oxadiazol-3-yl) phenyl)-2-hydroxyethyl)piperidin-3-yl)acetic acid, TFA (60); 2-((R)-1-((S)-2-(4-(5-(1-(6-chloropyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl) phenyl)-2-hydroxyethyl)piperidin-3-yl)acetic acid, HCl(61); 2-((R)-1-((S)-2-(4-(5-(1-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl)acetic acid, HCl(62); 2-((R)-1-((S)-2-(4-(5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-- 4-yl)-1,2,4-oxadiazol-3-yl)phenyl) -2-hydroxyethyl)piperidin-3-yl)acetic acid, HCl(63); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-- pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl) ethyl)piperidin-3-yl)acetic acid, tetrabutylammonium salt (64); 2-((R)-1-((S)-2-(4-(5-(1-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl) phenyl)-2-hydroxyethyl)piperidin-3-yl)acetic acid (65); 2-((R)-1-((S)-2-(4-(5-(1-(4-bromophenyl)-5-(trifluoromethyl)-1H-pyrazol-4- -yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl)acetic acid (66); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(1-m -tolyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)e- thyl) piperidin-3-yl)acetic acid, HCl(67); 2-((3R)-1-((2S)-2-hydroxy-2-(4-(5-(1-(2-methoxyphenyl)-5-(trifluoromethyl- )-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)aceti- c acid (68); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(1-(tetrahydro-2H-pyran-4-yl)-5-(trifluor- omethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl- )acetic acid (69); 2-((R)-1-((S)-2-(4-(5-(1-(5-chloropyridin-2-yl)-5-(trifluoromethyl)-1H-py- razol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl) piperidin-3-yl)acetic acid, HCl(70); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(1-(2,2,2-trifluoroethyl)-5-(trifluoromet-hyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl) ethyl)piperidin-3-yl)acetic acid, HCl(71); 2-((3R)-1-((2S)-2-(4-(5-(1-(2-chlorophenyl)-5-(trifluoromethyl)-1H -pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl- )acetic acid,HCl(72); 2-((3R)-1-((2S)-2-(4-(5-(1-(2,4-difluorophenyl)-5-(trifluoromethyl)-1H-py- razol-4-yl)-1,2,4-oxadiazol -3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl)acetic acid, HCl(73); 2-((3R)-1-((2S)-2-hydroxy-2-(4-(5-(5-(trifluoromethyl)-1-(2-(trifluoromet-hyl)phenyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-y1)phenyl)ethyl)piperidin-3- -yl)acetic acid, HCl(74); 2-((R)-1-(S)-2-hydroxy-2-(4-(5-(5-(trifluoromethyl)-1-(3-(trifluoromethyl- )phenyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl-)acetic acid, HCl(75); 2-((R)-1-(S)-2-hydroxy-2-(4-(5-(5-(trifluoromethyl)-1-(4-(trifluoromethyl- )phenyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl- )acetic acid (76); 2-((3R)-1-((2S)-2-hydroxy-2-(4-(5-(1-o-tolyl-5-(trifluoromethyl)-1H-pyraz- ol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid (77); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(1-p-tolyl-5-(trifluoromethyl)-1H-p-yrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid (78); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(1-(4-isopropylphenyl)-5-(trifluoro- methyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl) phenyl)ethyl)piperidin -3-yl)acetic acid (79); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(1-(4-methoxyphenyl)-5-(trifluoromethyl) -1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl) ethyl)piperidin-3-yl)acetic acid (80); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(1-isobutyl-5-(trifluoromethyl)-1H-pyrazo-l-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid, HCl(81); 2-((R)-1-((S)-2-(4-(5-(1-(5-fluoropyridin-2-yl) -5-(trifluoromethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydr- oxyethyl) piperidin-3-yl)acetic acid, HCl(82); 2-((3R)-1-((2S)-2-(4-(5-(1-(5-chloro-3-fluoropyridin-2-yl)-5-(trifluorome- thyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl) phenyl)-2-hydroxyethyl)piperidin-3-yl)acetic acid, HCl(83); 2-((3R)-1-((2S)-2-(4-(5-(1-(5-ethoxy-3-fluoropyridin-2-yl)-5-(trifluorome- thyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperid- in-3-yl)acetic acid, HCl(84); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(1-(pyrimidin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid (85); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(1-(pyridin-3-yl)-5-(trifluoromethyl)-1H-- pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid (86); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(5-(trifluoromethyl)-1-(5-(trifluor- omethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)p- iperidin-3-yl)acetic acid, HCl(87); 2-((3R)-1-((2S)-2-(4-(5-(1-(3,5-dichloropyridin-2-yl)-5-(trifluoromethyl)- -1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-- yl)acetic acid, HCl(88); 2-((3R)-1-((2S)-2-(4-(5-(1-(2,4-dichlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydr- oxyethyl)piperidin-3-y1)acetic acid, HCl(89); 2-((3R)-1-((2S)-2-(4-(5-(1-(4-chloro-2-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3- -yl)acetic acid, HCl(90); 2-((R)-1-((S)-2-(4-(5-(1-(4-chloro-3-methylphenyl)-5-(trifluoromethyl)-1H- -pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl)-acetic acid, HCl(91); 2-((R)-1-((S)-2-(4-(5-(1-(3,4-dichlorophenyl)-5-(trifluoromethyl)-1H-pyra- zol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl)aceti- c acid, HCl(92); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(1-(4-methylpyridin-2-yl)-5-(trifluoromet- hyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)ace- tic acid, HCl(93); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(1-(5-methylpyridin-2-yl)-5-(trifluoromet-hyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)ace- tic acid (94); 2-((3R)-1-((2S)-2-(4-(5-(1-(5-chloro-3-(trifluoromethyl)pyridin-2-yl)-5-(- trifluoromethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyet-hyl)piperidin-3-yl)acetic acid (95); 2-((R)-1-((S)-2-hydroxy-2-(4-(5-(1-(6-methyl-4-(trifluoromethyl)pyridin-2- -yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl )phenyl)ethyl)piperidin-3-yl)acetic acid, HCl(96); (S)-1-((S)-2-(4-(5-(1-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-y- l)-1,2,4-oxadiazol-3-yl) phenyl)-2-hydroxyethyl)piperidine-3-carboxylic acid, HCl(97); (S)-1-((S)-2-hydroxy-2-(4-(5-(5-(trifluoromethyl)-1-(5-(trifluoromethyl)p-yridin-2-yl)-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine- -3-carboxylic acid, HCl(98); (S)-1-((S)-2-hydroxy-2-(4-(5-(1-(4-methoxyphenyl)-5-(trifluoromethyl) -1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxyl- icacid, HCl(99); (S)-1-((S)-2-(4-(5-(1-(3,5-dichloropyridin-2-yl)-5-(trifluoromethyl)-1H-p- yrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidine-3-carb- oxylic acid, HCl(100); (S)-1-((S)-2-(4-(5-(1-(5-fluoropyridin-2-yl)-5-(trifluoromethyl)-1H-pyraz- ol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidine-3-carboxyl- ic acid, HCl(101); (S)-1-((S)-2-hydroxy-2-(4-(5-(1-m-tolyl-5-(trifluoromethyl)-1H-pyrazol-4--yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (102); (S)-1-((S)-2-hydroxy-2-(4-(5-(1-(5-methylpyridin-2-yl)-5-(trifluoromethyl-

)-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (103); (S)-1-((S)-2-hydroxy-2-(4-(5-(1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyr- azol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine -3-carboxylic acid(104); (S)-1-((S)-2-(4-(5-(1-(5-chloropyridin-2-yl)-5-(trifluoromethyl)-1- H -pyrazol-4-yl)-1,2,4-oxadiazol-3-yl) phenyl)-2-hydroxyethyl)piperidine-3-carboxylic acid (105); (S)-1-((S)-2-(4-(5-(1-cyclohexyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)-1,2-,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidine-3-carboxylic acid (106); (S)-1-((S)-2-(4-(5-(1-(2,4-difluorophenyl)-5-(trifluoromethyl)-1H-- pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidine-3-car- boxylic acid, HCl(107); 2-((R)-1-(S)-2-hydroxy-2-(4-(5-(5-isobutyl-4-(trifluoromethyl)isoxazol -3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl) piperidin-3-yl)acetic acid, TFA (108); 2-((R)-1-((S)-2-(4-(5-(5-tert-butyl-4-(trifluoromethyl)isoxazol-3--yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl) piperidin-3-yl)acetic acid, TFA (109); 2-((R)-1-(S)-2-hydroxy-2-(4-(5-(5-isopropyl-4-(trifluoromethyl)isoxazol-3- -yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid, HCl (110); 2-((R)-1-((S)-2-(4-(5-(5-cyclohexyl-4-(trifluoromethyl) isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl- )acetic acid, HCl(111); 2-((R)-1-((S)-2-(4-(5-(5-(3-chlorophenyl)-4-(trifluoromethyl)isoxazol-3-y-l)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl)acetic acid (112); 2-((3R)-1-((2S)-2-(4-(5-(5-(2-chlorophenyl)-4-(trifluoromethyl)iso- xazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl)ace- tic acid, HCl (113); (S)-1(S)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isothiazol-5-yl)-- 1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid, HCl (114); 2-((R)-1-(S)-2-hydroxy-2-(4-(5-(4-phenyl-5-(trifluoromethyl)thiophen-2-yl-)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid (115); 2-((R)-1-((S)-2-(4-(5-(1-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-- 4-yl) -1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl)acetic acid (116); 2-((R)-1-((S)-2-(4-(5-(1-(4-chlorophenyl)-5-(trifluoromethyl)-1H-imidazol- -4-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl)acetic acid (117); and 2-((R)-1-(S)-2-hydroxy-2-(4-(5-(1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-i-midazol-4-yl)-1,2,4-oxadiazol-3-yl)phenyl) ethyl)piperidin-3-yl)acetic acid (118).

11. A pharmaceutical composition comprising a compound according to claim 1 or stereoisomers or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
Description:
 
 
  Recently Added Patents
Systems and methods for arranging and labeling cardiac episodes
Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
Integrated projector system
Level-shift circuit, electro-optical device, and level shift method
Protein kinase C inhibitors and uses thereof
Materials and methods for stress reduction in semiconductor wafer passivation layers
Enhancement of semiconducting photovoltaic absorbers by the addition of alkali salts through solution coating techniques
  Randomly Featured Patents
Cutting insert and holders therefor
Content reflection display systems
Intravascular radially expandable stent
Wire rope for running wire
Cash replacement system including an encoded card and card acceptor
Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
Reference microplates and methods for making and using the reference microplates
Method of manufacturing corrosion-resistant measuring probes
Exercise apparatus
Method and apparatus for transcutaneous electrical cardiac pacing